In this video presentation, Dr. Gladstone C. McDowell, II* explains important topics for discussion with your patients, including patient counseling and setting expectations. Dr. McDowell is the Medical Director of Integrated Pain Solutions in Columbus, Ohio.
Patient counseling, including setting patient expectations, is an important component to the initiation of PRIALT therapy. Inform your patients that PRIALT, a non-opioid medication, is a well-studied IT medication that is approved by the FDA for the treatment of severe chronic pain in adults. Patients should understand that it may take some time to achieve adequate pain relief. Finding the effective dose is an ongoing process tailored to the individual patient’s response, severity of pain, as well as side effects.
*Gladstone C. McDowell, II, MD is a paid consultant for Jazz Pharmaceuticals.
PRIALT® (ziconotide) intrathecal infusion (25mcg/mL, 100mcg/mL) is indicated for the management of severe chronic pain in adult patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine.
PRIALT® (ziconotide) solution, intrathecal infusion [packet insert]. Palo Alto, CA: Jazz Pharmaceuticals